Advances in PAH: What PAs Need to Know to Improve Care
Maggiano's Little Italy
16405 North Scottsdale Road
Scottsdale, AZ 85254
Thursday, November 6, 2025 at 6:00pm MT - 8:00pm MT
Add this event to your calendar
Info
Topic
Pulmonary Arterial Hypertension (PAH) is a rare and progressive disease that affects the small pulmonary arterioles. It is challenging to diagnose and complex to manage. This accredited CE activity will review the pathophysiology and classifications of PAH, along with current therapies and the management of common side effects. Disparities in care will also be addressed, as well as how risk assessment is calculated and used to help achieve and maintain a low-risk status—an essential treatment goal for patients with PAH.
Credits Offered
This event offers
1.0 CME credit
to attendees.
Accreditation Info:
AAPA.
Additional Information
Intended Audience
The intended audience includes nurse practitioners, nurses, physician assistants and other providers involved in the management of patients with pulmonary arterial hypertension (PAH).
Educational Objectives
After completing of the educational activity, participants should be able to:
- Identify the newest diagnostic criteria and classification of PAH.
- Plan effective care for patients with PAH that considers the side effect profile, method of dosing and administration, adverse events, and disparities.
- Summarize updated treatment pathways and therapeutic targets in the management of PAH.
Commercial Supporter: This activity is supported by an educational grant from Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc., and Johnson & Johnson.
Speakers
Family Nurse Practitioner
Pulmonary Hypertension Clinic
University of Texas Southwestern Medical Center
Nurse Practitioner, Pulmonary Services, Heart and Lung Center